JOHNSON & JOHNSON is 305.3x more valuable than Sarepta Therapeutics, Inc. by market capitalization ($573.98 B vs $1.88 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | SRPT | JNJ |
|---|---|---|
| Market cap | $1.88 B | $573.98 B |
| US-listed rank | #2138 | #20 |
| Revenue (latest FY) | $1.86B | $94.19B |
| Net income (latest FY) | -$713.41M | $26.80B |
| Net margin | -38.3% | 28.5% |
| P/E (trailing FY) | - | 21.4 |
| SEC filings | 1,504 | 984 |
JOHNSON & JOHNSON is 305.3x more valuable than Sarepta Therapeutics, Inc. by market capitalization ($573.98 B vs $1.88 B).
In their latest fiscal years, Sarepta Therapeutics, Inc. reported $1.86B in revenue while JOHNSON & JOHNSON reported $94.19B.
Full pages: Sarepta Therapeutics, Inc. and JOHNSON & JOHNSON, or browse the full rankings.